<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100527</url>
  </required_header>
  <id_info>
    <org_study_id>B1731019</org_study_id>
    <nct_id>NCT02100527</nct_id>
  </id_info>
  <brief_title>Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris</brief_title>
  <official_title>A Phase 2a Randomized, Double-blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Effects Of PF-05175157 On Moderate To Severe Acne Vulgaris In Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157
      administered for 6 weeks in subjects with moderate to severe acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study canceled
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Weeks 2, 4, and 6</time_frame>
    <description>Physical examination, pulmonary function testing, adverse event monitoring, ECGs, vital signs, laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sebum measurements</measure>
    <time_frame>Weeks 2, 4, and 6</time_frame>
    <description>Change from baseline in amount and rate of sebum excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PF-05175157</measure>
    <time_frame>Weeks 2, 4, and 6</time_frame>
    <description>Plasma concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>PF-05175157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks</description>
    <arm_group_label>PF-05175157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 18 years or older diagnosed with moderate to severe acne vulgaris who are
             otherwise healthy.

          -  Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80%
             predicted).

          -  Minimum of 20 inflammatory lesions on the face.

          -  Willing to discontinue other acne treatments prior to and during the study period
             through follow-up.

        Exclusion Criteria:

          -  Subjects with active nodulocystic acne.

          -  Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and
             perform study procedures.

          -  History of dry eye or other known disease that affects the sclera or cornea.

          -  History of pulmonary disease or inability to adequately perform testing.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731019&amp;StudyName=Study%20Of%20Safety%2C%20Tolerability%20And%20Effects%20Of%20PF-05175157%20In%20Adults%20With%20Moderate%20To%20Severe%20Acne%20Vulgaris</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>oral dosing</keyword>
  <keyword>moderate to severe acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

